ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period
Latest Information Update: 31 Oct 2024
At a glance
- Drugs Navepegritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms ACcomplisH
- Sponsors Ascendis Pharma
- 29 Oct 2024 Status changed from active, no longer recruiting to completed.
- 24 Jun 2024 According to an Ascendis Pharma media release, company announced the oral presentation of data from this trial during ICCBH 2024, the International Conference on Childrens Bone Health being held in Salzburg, Austria.
- 20 Dec 2023 According to an Ascendis Pharma media release, further details of the results will be shared early next year.